Venous thromboembolic complications in lymphoma patients

摘要: Lymphomas represent a heterogeneous group of malignant hematological diseases with high risk for development venous thromboembolic complications (VTE). Consequently, VTE significantly impacts morbidity and mortality in these patients. Another concern is the financial burden healthcare system caused by diagnostic therapeutic procedures cancer-associated thrombosis (CAT). The complex biology lymphoma, conjunction patient treatment related factors VTE, results procoagulant hemostatic dysregulation. Considering incidence patients there an emerging demand both reliable risks assessment model (RAM) prediction as well effective prophylaxis treatment. clinical course accompanied wide range potential complications, making task prevention even more challenging. In recent years, great progress has been achieved understanding pathophysiological mechanisms thrombotic while significant number randomized controlled trials (RCT) have provided standards malignancy. comparison to previous recommendations guidelines CAT, use direct oral anticoagulants (DOAC) gradually approaching low molecular weight heparins (LMWH) terms efficacy safety profile indications. This systematic review focused on latest advances, assessment, prophylactic concerning lymphoma.